Abstract

It was with great interest that we read the article from Faria et al 1 on the cost-effectiveness of robotic-assisted radical prostatectomy (RP) for localized prostate cancer from the Brazilian Public Health System (Sistema Único de Saúde [SUS]) perspective, published in May 2022 by Value in Health Regional Issues. Evidence of the high-end technologies’ cost-effectiveness in the Brazilian context is always welcome. Nevertheless, we were very surprised by the low incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) for the comparisons with both open and laparoscopic techniques estimated in this study. We proceeded to carefully analyze the results, assumptions, and data sources used by the authors and found some points that we believe are worthy of attention.